Company Description
QuidelOrtho Corporation provides diagnostic testing solutions.
The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units.
The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases.
The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings.
The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics.
The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use.
It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1979 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7,100 |
| CEO | Brian Blaser |
Contact Details
Address: 9975 Summers Ridge Road San Diego, California 92121 United States | |
| Phone | 858 552 1100 |
| Website | quidelortho.com |
Stock Details
| Ticker Symbol | QDEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001906324 |
| CUSIP Number | 219798105 |
| ISIN Number | US2197981051 |
| Employer ID | 87-4496285 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Brian J. Blaser | President, Chief Executive Officer and Director |
| Dr. Werner Kroll Ph.D. | Executive Officer |
| Michael S. Iskra | Executive Vice President and Chief Commercial Officer |
| Jonathan Siegrist Ph.D. | Executive Vice President of Research and Development and Chief Technology Officer |
| Juliet C. Cunningham | Vice President of Investor Relations |
| Michelle A. Hodges J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Ronald Lee Bowman | Chief Human Resources Officer |
| William J. Ferenczy | Point of Care Business Unit Leader |
| Tamara A. Ranalli | Molecular Diagnostics Business Unit Leader |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 424B3 | Prospectus |
| Nov 19, 2024 | FWP | Free Writing Prospectus |
| Nov 19, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K/A | [Amend] Current report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 10-Q | Quarterly Report |